Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 vs placebo in global and regional lung function and gas exchange in moderate to severe COPD
2013-004461-13Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Global lung ventilation volume. Started Nov 2015; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-004461-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004461-13.